164 related articles for article (PubMed ID: 37103690)
1. Split-face comparison of hydroquinone 4% plus nitrogen plasma vs. hydroquinone 4% alone in the treatment of melasma.
Yousefi M; Hadian K; Babossalam S; Diab R; Akhlaghi M; Aghighi M; Abdollahimajd F; Shokri B
Lasers Med Sci; 2023 Apr; 38(1):113. PubMed ID: 37103690
[TBL] [Abstract][Full Text] [Related]
2. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
[TBL] [Abstract][Full Text] [Related]
3. Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: A split-face comparative study.
Tekam PS; Belgaumkar VA
Dermatol Ther; 2022 Nov; 35(11):e15761. PubMed ID: 36068674
[TBL] [Abstract][Full Text] [Related]
4. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Shihab N; Prihartono J; Tovar-Garza A; Agustin T; Legiawati L; Pandya AG
Australas J Dermatol; 2020 Aug; 61(3):237-242. PubMed ID: 32109318
[TBL] [Abstract][Full Text] [Related]
5. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Banihashemi M; Zabolinejad N; Jaafari MR; Salehi M; Jabari A
J Cosmet Dermatol; 2015 Sep; 14(3):174-7. PubMed ID: 26177992
[TBL] [Abstract][Full Text] [Related]
6. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
Lueangarun S; Namboonlue C; Tempark T
J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
[TBL] [Abstract][Full Text] [Related]
7. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
[TBL] [Abstract][Full Text] [Related]
8. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma.
Arrowitz C; Schoelermann AM; Mann T; Jiang LI; Weber T; Kolbe L
J Invest Dermatol; 2019 Aug; 139(8):1691-1698.e6. PubMed ID: 30825454
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma.
Ibrahim ZA; Gheida SF; El Maghraby GM; Farag ZE
J Cosmet Dermatol; 2015 Jun; 14(2):113-23. PubMed ID: 25847063
[TBL] [Abstract][Full Text] [Related]
10. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
Adalatkhah H; Sadeghi-Bazargani H
Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
[TBL] [Abstract][Full Text] [Related]
11. Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma.
Taghavi F; Banihashemi M; Zabolinejad N; Salehi M; Jaafari MR; Marhamati H; Golnouri F; Dorri M
J Cosmet Dermatol; 2019 Jun; 18(3):870-873. PubMed ID: 30105847
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.
Yasnova N; Sirait SP; Rahmayunita G
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):83-88. PubMed ID: 38918942
[TBL] [Abstract][Full Text] [Related]
13. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
Saki N; Darayesh M; Heiran A
J Dermatolog Treat; 2018 Jun; 29(4):405-410. PubMed ID: 29027510
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.
Sepaskhah M; Karimi F; Bagheri Z; Kasraee B
J Cosmet Dermatol; 2022 Jul; 21(7):2871-2878. PubMed ID: 35510765
[TBL] [Abstract][Full Text] [Related]
15. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study.
Abd Elraouf IG; Obaid ZM; Fouda I
Arch Dermatol Res; 2023 Aug; 315(6):1763-1770. PubMed ID: 36856856
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
Lima PB; Dias JAF; Cassiano DP; Esposito ACC; Miot LDB; Bagatin E; Miot HA
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1881-1887. PubMed ID: 33988887
[TBL] [Abstract][Full Text] [Related]
17. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
Grimes P; Watson J
Cutis; 2013 Jan; 91(1):47-54. PubMed ID: 23461059
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Wattanakrai P; Nimmannitya K
J Drugs Dermatol; 2022 Dec; 21(12):1304-1310. PubMed ID: 36468967
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
